BRPI0909375A2 - Moduladores de receptores de quimiocinas - Google Patents
Moduladores de receptores de quimiocinasInfo
- Publication number
- BRPI0909375A2 BRPI0909375A2 BRPI0909375-3A BRPI0909375A BRPI0909375A2 BR PI0909375 A2 BRPI0909375 A2 BR PI0909375A2 BR PI0909375 A BRPI0909375 A BR PI0909375A BR PI0909375 A2 BRPI0909375 A2 BR PI0909375A2
- Authority
- BR
- Brazil
- Prior art keywords
- chemokine receptor
- receptor modulators
- modulators
- chemokine
- receptor
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title 1
- 108050000299 Chemokine receptor Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4051608P | 2008-03-28 | 2008-03-28 | |
| PCT/US2009/038805 WO2009121063A2 (en) | 2008-03-28 | 2009-03-30 | Chemokine receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0909375A2 true BRPI0909375A2 (pt) | 2015-08-04 |
Family
ID=41114825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909375-3A BRPI0909375A2 (pt) | 2008-03-28 | 2009-03-30 | Moduladores de receptores de quimiocinas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8338448B2 (enExample) |
| EP (2) | EP2262808B1 (enExample) |
| JP (1) | JP5690715B2 (enExample) |
| KR (1) | KR20110005819A (enExample) |
| CN (1) | CN102015717A (enExample) |
| AU (1) | AU2009228034A1 (enExample) |
| BR (1) | BRPI0909375A2 (enExample) |
| CA (1) | CA2718618A1 (enExample) |
| DK (1) | DK2262808T3 (enExample) |
| IL (1) | IL208185A0 (enExample) |
| MX (1) | MX2010010619A (enExample) |
| NZ (1) | NZ587929A (enExample) |
| SG (1) | SG189723A1 (enExample) |
| WO (1) | WO2009121063A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100518160B1 (ko) * | 1996-11-05 | 2006-09-18 | 닛폰 프라파렛트 가부시키가이샤 | 합성수지팔레트 |
| AU2009228034A1 (en) | 2008-03-28 | 2009-10-01 | Altiris Therapeutics | Chemokine receptor modulators |
| EP2646430B1 (en) | 2010-12-03 | 2016-09-21 | Emory University | Chemokine cxcr4 receptor modulators and uses related thereto |
| EP3915987B1 (en) * | 2013-03-14 | 2023-12-13 | Osteoqc Inc. | Alkyl-amine harmine derivatives for promoting bone growth |
| US10450293B2 (en) | 2014-05-16 | 2019-10-22 | Emory University | Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto |
| US9862703B2 (en) * | 2014-09-22 | 2018-01-09 | National Health Research Institutes | Heterocyclic compounds and use thereof |
| JP6958820B2 (ja) | 2015-12-14 | 2021-11-02 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP7055380B2 (ja) | 2015-12-22 | 2022-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 免疫不全疾患を処置するための方法 |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| EP3321264A1 (en) * | 2016-11-14 | 2018-05-16 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
| EP3585387A4 (en) * | 2017-02-21 | 2020-08-12 | Emory University | CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES |
| US12384830B2 (en) | 2017-06-02 | 2025-08-12 | Regents Of The University Of Minnesota | Compositions and methods for improving immunotherapy |
| CN109553604B (zh) * | 2017-09-25 | 2021-08-27 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用 |
| CN110669036B (zh) * | 2018-07-02 | 2022-02-11 | 盛世泰科生物医药技术(苏州)有限公司 | 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用 |
| WO2019060860A1 (en) * | 2017-09-25 | 2019-03-28 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF |
| JP7282786B2 (ja) * | 2017-09-25 | 2023-05-29 | シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド | Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法 |
| WO2019183133A1 (en) | 2018-03-19 | 2019-09-26 | Emory University | Pan-Tropic Entry Inhibitors |
| AU2019321434B2 (en) | 2018-08-14 | 2025-05-08 | Ossifi Therapeutics Llc | Pyrrolo - dipyridine compounds |
| EP3837241A4 (en) | 2018-08-14 | 2022-05-18 | Osteoqc Inc. | FLUOROUS SS CARBOLINE COMPOUNDS |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
| US20240293391A1 (en) * | 2021-06-24 | 2024-09-05 | Katholieke Universiteit Leuven | Isoquinoline and pyridine based cxcr4 antagonists |
| WO2024220485A2 (en) * | 2023-04-18 | 2024-10-24 | The Regents Of The University Of California | Dual inhibitors of dyrk1a and 5-ht2 for treating a brain disorder |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| US5631265A (en) | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
| US5993817A (en) | 1995-01-23 | 1999-11-30 | Xenotech | Method to ameliorate osteolysis and metastasis |
| US6358915B1 (en) | 1995-03-07 | 2002-03-19 | George Washington University | Methods for inhibiting metastasis |
| WO1997000956A1 (en) | 1995-06-20 | 1997-01-09 | Trustees Of Boston University | Hypoxia-responsive adhesion molecules, specific antibodies, and their uses |
| US6344545B1 (en) | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
| US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
| AU1616499A (en) | 1997-12-01 | 1999-06-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chemokine variants and methods of use |
| WO1999047158A2 (en) | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| AU759144B2 (en) | 1998-05-05 | 2003-04-03 | Adherex Technologies Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| WO2000031271A1 (en) | 1998-11-24 | 2000-06-02 | Hisamitsu Pharmaceutical Co., Inc. | Hiv infection inhibitors |
| CA2368047A1 (en) | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| US6750348B1 (en) | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| EP2275447A1 (en) | 1999-11-24 | 2011-01-19 | Schering Corporation | Methods of inhibiting metastasis |
| US20030220482A1 (en) | 2000-02-03 | 2003-11-27 | Ziwei Huang | Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II |
| DE60103052T2 (de) | 2000-05-09 | 2005-03-03 | The University Of British Columbia, Vancouver | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten |
| NZ524421A (en) | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| US20040157818A1 (en) | 2001-05-24 | 2004-08-12 | Mikiro Yanaka | Cxcr4-antagonistic drugs composed of nitrogen-containing compound |
| JPWO2003029218A1 (ja) | 2001-09-28 | 2005-01-13 | 呉羽化学工業株式会社 | 新規含窒素化合物及びその用途 |
| MXPA04006136A (es) * | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| EP1541585B1 (en) | 2002-08-27 | 2013-01-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
| DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| US20040132642A1 (en) | 2002-11-12 | 2004-07-08 | Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services | Methods of inhibiting metastasis or growth of a tumor cell |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| JP2006524242A (ja) | 2003-03-27 | 2006-10-26 | エモリー ユニバーシティー | Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法 |
| WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| EP2374804A1 (en) | 2003-04-22 | 2011-10-12 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2005048916A2 (en) * | 2003-11-20 | 2005-06-02 | Biovitrum Ab | Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders |
| US8008312B2 (en) | 2005-01-07 | 2011-08-30 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| MX2007008328A (es) | 2005-01-07 | 2008-01-16 | Univ Emory | Antagonistas cxcr4 para el tratamiento de trastornos medicos. |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| US20080227799A1 (en) | 2006-07-11 | 2008-09-18 | Liotta Dennis C | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders |
| WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| US20080261978A1 (en) | 2007-03-08 | 2008-10-23 | Clark Michael P | Chemokine receptor modulators |
| WO2008112156A1 (en) | 2007-03-08 | 2008-09-18 | Altiris Therapeutics | Chemokine receptor modulators |
| AU2009228034A1 (en) | 2008-03-28 | 2009-10-01 | Altiris Therapeutics | Chemokine receptor modulators |
-
2009
- 2009-03-30 AU AU2009228034A patent/AU2009228034A1/en not_active Abandoned
- 2009-03-30 JP JP2011502132A patent/JP5690715B2/ja not_active Expired - Fee Related
- 2009-03-30 SG SG2013023692A patent/SG189723A1/en unknown
- 2009-03-30 WO PCT/US2009/038805 patent/WO2009121063A2/en not_active Ceased
- 2009-03-30 EP EP09724705.0A patent/EP2262808B1/en not_active Not-in-force
- 2009-03-30 EP EP13174241.3A patent/EP2664618A3/en not_active Withdrawn
- 2009-03-30 BR BRPI0909375-3A patent/BRPI0909375A2/pt not_active IP Right Cessation
- 2009-03-30 CN CN2009801150516A patent/CN102015717A/zh active Pending
- 2009-03-30 NZ NZ587929A patent/NZ587929A/xx not_active IP Right Cessation
- 2009-03-30 DK DK09724705.0T patent/DK2262808T3/da active
- 2009-03-30 KR KR1020107023643A patent/KR20110005819A/ko not_active Ceased
- 2009-03-30 MX MX2010010619A patent/MX2010010619A/es active IP Right Grant
- 2009-03-30 CA CA2718618A patent/CA2718618A1/en not_active Abandoned
- 2009-03-30 US US12/414,352 patent/US8338448B2/en not_active Expired - Fee Related
-
2010
- 2010-09-16 IL IL208185A patent/IL208185A0/en unknown
-
2012
- 2012-11-15 US US13/677,944 patent/US9314468B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010010619A (es) | 2010-12-17 |
| JP5690715B2 (ja) | 2015-03-25 |
| DK2262808T3 (da) | 2013-11-04 |
| AU2009228034A1 (en) | 2009-10-01 |
| US8338448B2 (en) | 2012-12-25 |
| SG189723A1 (en) | 2013-05-31 |
| EP2262808A4 (en) | 2011-11-16 |
| WO2009121063A3 (en) | 2010-01-07 |
| US20100029634A1 (en) | 2010-02-04 |
| US9314468B2 (en) | 2016-04-19 |
| KR20110005819A (ko) | 2011-01-19 |
| CA2718618A1 (en) | 2009-10-01 |
| EP2262808B1 (en) | 2013-08-14 |
| EP2262808A2 (en) | 2010-12-22 |
| JP2011516427A (ja) | 2011-05-26 |
| EP2664618A3 (en) | 2014-05-07 |
| IL208185A0 (en) | 2010-12-30 |
| WO2009121063A2 (en) | 2009-10-01 |
| US20130172330A1 (en) | 2013-07-04 |
| EP2664618A2 (en) | 2013-11-20 |
| NZ587929A (en) | 2012-10-26 |
| CN102015717A (zh) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0909375A2 (pt) | Moduladores de receptores de quimiocinas | |
| BRPI0923305A2 (pt) | moduladores de receptores toll-like | |
| DK2297100T3 (da) | Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer | |
| BR112012008159A2 (pt) | moduladores de receptor canabinoide | |
| BRPI0907844A2 (pt) | moduladores seletivos do receptor de andrógeno | |
| BRPI0909644A2 (pt) | dispositivo de foto-epilação | |
| BR112012010640A2 (pt) | novos moduladores de quinase | |
| BRPI0917394A2 (pt) | moduladores de mif | |
| BRPI0908169A2 (pt) | técnicas de iniciação de serviço | |
| ATE537157T1 (de) | Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| BRPI0921815A2 (pt) | compostos receptores de apj | |
| BRPI0908815A2 (pt) | inibidores do receptor de quimiocina cxcr3 | |
| GB0701992D0 (en) | Grehlin Receptor Modulators | |
| BRPI0822525A2 (pt) | gerar mapas de sites | |
| BRPI0906734A2 (pt) | Dispositivo de virola | |
| BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
| BR112012009661A2 (pt) | derivados de diazepam como moduladores de receptores de quimiocina | |
| ZA201104069B (en) | 3-aminocyclopentanecarboxamides as chemokine receptor modulators | |
| ES1069364Y (es) | Dispositivo de garantia | |
| PL2288612T3 (pl) | Modulatory receptora GABAA | |
| DE602007008589D1 (de) | Pyridooxazepin-progesteronrezeptor-modulatoren | |
| BRPI0920825A2 (pt) | modulador seletivo do receptor de estrogênio | |
| EP2345824A4 (en) | CLUTCH SUPPORT STRUCTURE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/040,516 DE 28/03/2008 REIVINDICADA NO PCT/US2009/038805, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 17/03/2011, CONTUDO O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 26/11/2010 (60 DIAS APOS O DEPOSITO DE ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISPOSICOES PREVISTAS NA |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |